Abstract
Our findings illustrate that the long-term survival of gastric cancer (GC) has improved in China since 2000. Hospital-based studies have presented higher survival rates (SRs) than population-based surveillance, reflecting the impact of clinical intervention and specialized care.
Introduction
Gastric cancer (GC) remains a primary public health crisis in China, accounting for over 370,000 deaths annually. While mortality rates are declining in many industrialized nations, China’s aging population and the high prevalence of Helicobacter pylori infection maintain a significant disease burden.
Historically, a "data gap" has existed in understanding GC prognosis across China. Population-based cancer registries often suffer from incomplete follow-up, potentially biasing survival statistics downward. Conversely, hospital-based studies provide granular clinical detail—such as TNM staging and specific therapy types—but are often localized. This systematic review and meta-analysis seeks to bridge this gap by providing a nationwide, longitudinal synthesis of hospital-based survival data from 2000 to 2022.
Methods
The researchers conducted a systematic review and meta-analysis following PRISMA guidelines to map the landscape of GC survival in China.
Search Strategy and Selection
The team queried international databases (PubMed, Embase, Web of Science) and major Chinese databases (CNKI, Wanfang) for studies published between 2000 and 2022. Inclusion criteria required studies to be hospital-based, involve ethnically Chinese participants, and provide clear survival rate (SR) data.
Quality Assessment and Analytics
Studies were vetted using a modified Newcastle-Ottawa Scale (NOS), with only those scoring $\ge 4$ included. Random-effects models (DerSimonian-Laird method) were employed to account for expected high heterogeneity. Subgroup analyses were performed based on TNM stage, histological type, geographical region, and time period.
Results
The study synthesized data from 664 original studies involving a total of 180,798 participants. This massive participant pool provided nationwide coverage, with significant data from high-prevalence provinces such as Shandong, Fujian, Liaoning, Gansu, and Jiangsu.
Pooled Survival Rates and Temporal Trends
The meta-analysis revealed the following pooled survival rates:
- 1-year: 75.4%
- 3-year: 53.4%
- 5-year: 44.5%
A clear "turning point" was observed around 2006, after which 3-year and 5-year survival rates began a steady climb. This likely reflects advancements in surgical techniques, such as laparoscopic and robotic gastrectomy, alongside improved adjuvant therapies.
The Staging Cliff and Histology
The data underscores the critical impact of early staging. The 5-year survival rate for Stage I patients is 83.9%, but this drops precipitously to just 9.1% for Stage IV. Furthermore, patients without lymph node metastasis showed a 5-year survival rate of 67.8%, compared to 8.4% for those with distant metastasis. Regarding histology, gastric adenocarcinoma (GA) demonstrated a significantly better prognosis than signet ring cell carcinoma (SRCC).
Discussion
A striking insight from this study is the "hospital advantage": survival rates in hospital-based studies are significantly higher than those in population-based registries. This suggests that patients accessing specialized hospital care benefit from clinical interventions that general registries may not capture, or that registries include more "lost-to-follow-up" cases.
Interestingly, regions with the highest GC prevalence often showed better survival rates, suggesting that a higher local burden leads to increased investment in screening and clinical expertise.
Limitations
The study noted high heterogeneity ($I^2 > 90\%$), reflecting variations in clinical settings and follow-up rigor. Additionally, publication bias remains a factor, as positive outcomes are more likely to be published. The evolution of TNM staging standards over the 22-year period also introduces potential longitudinal "noise."
Conclusion
While hospital care and long-term survival are improving, China still lacks a unified nationwide screening program comparable to those in Japan or South Korea. Future public health efforts should prioritize standardized early detection to shift diagnoses from late-stage categories to highly survivable early stages.
Summary updated